Summary

Ischemic Stroke Surgery Market Research Report by Type of Surgery (Thrombectomy, Revascularization Surgery, Carotid Endarterectomy, Angioplasty, Others), by Product Type (Catheters, Aspiration System, Guidewire, Microcatheter, Others), by End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2035

Market Analysis
The global ischemic stroke surgery market recorded USD 2,291.16 million and is expected to grow to USD 7,266.15 million with a CAGR of 8.70% during the forecast period. Ischemic stroke surgery involves clearing blocked arteries to restore normal blood flow to the brain. This procedure plays a vital role in minimizing brain damage and supporting patient recovery.
The global ischemic stroke surgery market is growing due to a rise in physical inactivity and sedentary habits, which increase stroke risks. The introduction of advanced surgical tools and technology is improving treatment outcomes. There's also a growing preference for minimally invasive procedures.
However, the global ischemic stroke surgery industry faces challenges from limited healthcare facilities and a lack of trained professionals. On the other hand, ongoing research and rising investments are opening new growth opportunities in the global ischemic stroke surgery market.

Market Segmentation Insights
The global ischemic stroke surgery market is segmented based on the type of surgery, including Thrombectomy, Revascularization Surgery, Carotid Endarterectomy, Angioplasty, and others.
In terms of product type, the global market is divided into Catheters, aspiration systems, guidewires, microcatheters, and others.
Depending on the end-users, the global ischemic stroke surgery market is classified into hospitals and clinics, ambulatory surgical centers, and others.

Regional Perspectives
The North American region is witnessing strong growth in the global ischemic stroke surgery market due to the rising number of stroke cases and increasing demand for advanced treatments like endovascular thrombectomy. With growing awareness, technological advancements, and a large aging population, the region continues to lead in stroke care innovations.
Europe is advancing the global ischemic stroke surgery market through groundbreaking research and innovative treatment methods like thrombectomy. With rising stroke cases and strong support for medical research, the region is strengthening its role in improving stroke care outcomes.
The Asia-Pacific region is driving growth in the global ischemic stroke surgery market with rising stroke cases and increasing government focus on healthcare. Ongoing clinical research and growth in access to advanced care is reported to be that which is improving stroke results in countries like India, Japan, and South Korea.
The rest of the world, like Africa, Latin America, and the Middle East, is experiencing an increase in the number of cardiovascular diseases and strokes, which can stimulate the demand for ischemic stroke surgeries. As health care initiatives grow and we see development in health care infrastructure, which is a trend in these regions, they are in fact becoming key players in the global ischemic stroke surgery market.

Major Competitors
Key players in the global ischemic stroke surgery market are Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., Stryker, Imperative Care, Johnson & Johnson Services Inc., Penumbra, Inc., and Phenox GmbH.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY .................................. 14
1.1 OVERVIEW ............................................................................. 14
2 MARKET INTRODUCTION ............................... 15
2.1 DEFINITION ........................................................................... 15
2.2 SCOPE OF THE STUDY ........................................................... 15
2.3 RESEARCH OBJECTIVE .......................................................... 15
2.4 MARKET STRUCTURE ............................................................. 15
2.5 ASSUMPTIONS & LIMITATIONS .............................................. 16
3 RESEARCH METHODOLOGY ......................... 17
3.1 DATA MINING ........................................................................ 17
3.2 SECONDARY RESEARCH ........................................................ 18
3.3 PRIMARY RESEARCH ............................................................. 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS ............................. 19
3.5 FORECASTING TECHNIQUES .................................................. 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION ... 21
3.6.1 BOTTOM-UP APPROACH .................................................... 21
3.6.2 TOP-DOWN APPROACH ..................................................... 22
3.7 DATA TRIANGULATION .......................................................... 23
3.8 VALIDATION .......................................................................... 23
4 MARKET DYNAMICS ....................................... 24
4.1 OVERVIEW ............................................................................. 24
4.2 DRIVERS ................................................................................ 25
4.2.1 RISE IN PHYSICAL INACTIVITY AND SEDENTARY LIFESTYLES .......................................................................... 25
4.2.2 ADOPTION AND LAUNCH OF TECHNOLOGICALLY ADVANCED PRODUCTS ........................................................ 25
4.2.3 RISING DEMAND FOR MINIMALLY INVASIVE PROCEDURES .............................................................................. 26
4.3 RESTRAINTS ......................................................................... 27
4.3.1 LACK OF MEDICAL FACILITIES ........................................... 27
4.3.2 SHORTAGE OF SKILLED PROFESSIONALS ........................... 28
4.4 OPPORTUNITIES .................................................................... 29
4.4.1 R&D ACTIVITIES AND INVESTMENTS .................................. 29
5 MARKET FACTOR ANALYSIS ......................... 30
5.1 VALUE CHAIN ANALYSIS ....................................................... 30
5.1.1 R&D ..... 31
5.1.2 MANUFACTURING ............................................................. 31
5.1.3 DISTRIBUTION AND SALES ................................................. 31
5.1.4 POST-SALES MONITORING ................................................ 31
5.2 PORTER’S FIVE FORCES MODEL ............................................. 32
5.2.1 THREAT OF NEW ENTRANTS .............................................. 32
5.2.2 BARGAINING POWER OF SUPPLIERS .................................. 33
5.2.3 THREAT OF SUBSTITUTES ................................................. 33
5.2.4 BARGAINING POWER OF BUYERS ....................................... 33
5.2.5 INTENSITY OF RIVALRY ..................................................... 33
5.3 IMPACT OF COVID-19 ON THE GLOBAL ISCHEMIC STROKE SURGERY MARKET ..................................................... 33
5.3.1 IMPACT ON SUPPLY CHAIN ............................................... 33
5.3.2 IMPACT ON PRODUCTION .................................................. 34
5.3.3 IMPACT ON DEMAND ........................................................ 34
5.4 EPIDEMIOLOGY ANALYSIS ..................................................... 34
5.4.1 INCIDENCE & PREVALENCE ................................................ 34
5.4.2 NUMBER OF PROCEDURES FOR THROMBECTOMY .............. 35
5.5 REGULATORY ANALYSIS/HEALTHCARE SYSTEM .................... 36
6 GLOBAL ISCHEMIC STROKE SURGERY MARKET, BY TYPE OF SURGERY ........................... 37
6.1 OVERVIEW ............................................................................. 37
6.2 THROMBECTOMY .................................................................. 38
6.3 REVASCULARIZATION SURGERY............................................. 38
6.4 CAROTID ENDARTERECTOMY ................................................. 39
6.5 ANGIOPLASTY ....................................................................... 40
6.6 OTHERS ................................................................................ 41
7 GLOBAL ISCHEMIC STROKE SURGERY MARKET, BY PRODUCT TYPE ................................. 42
7.1 OVERVIEW ............................................................................. 42
7.2 CATHETER ............................................................................ 43
7.3 ASPIRATION SYSTEM ............................................................ 43
7.4 GUIDEWIRE ............................................................................ 44
7.5 MICROCATHETER .................................................................. 45
7.6 OTHERS ................................................................................ 45
8 GLOBAL ISCHEMIC STROKE SURGERY MARKET, BY END USER ........................................... 46
8.1 OVERVIEW ............................................................................. 46
8.2 HOSPITALS AND CLINICS ...................................................... 47
8.3 AMBUATORY SURGICAL CENTRES .......................................... 47
8.4 OTHERS ................................................................................ 49
9 GLOBAL ISCHEMIC STROKE SURGERY MARKET, BY REGION ............................................... 50
9.1 OVERVIEW ............................................................................. 50
9.2 NORTH AMERICA ................................................................... 52
9.2.1 US........ 54
9.2.2 CANADA ........................................................................... 55
9.3 EUROPE ................................................................................ 57
9.3.1 GERMANY ......................................................................... 59
9.3.2 UK ....... 60
9.3.3 FRANCE ............................................................................ 61
9.3.4 ITALY ................................................................................ 62
9.3.5 SPAIN ............................................................................... 63
9.3.6 REST OF EUROPE ............................................................... 64
9.4 ASIA PACIFIC ........................................................................ 66
9.4.1 JAPAN .............................................................................. 68
9.4.2 CHINA ............................................................................... 69
9.4.3 INDIA ................................................................................ 70
9.4.4 AUSTRALIA ....................................................................... 71
9.4.5 SOUTH KOREA ................................................................... 72
9.4.6 REST OF ASIA PACIFIC....................................................... 73
9.5 REST OF THE WORLD ............................................................. 75
9.5.1 MIDDLE EAST .................................................................... 77
9.5.2 AFRICA ............................................................................. 78
9.5.3 LATIN AMERICA ................................................................ 79
10 COMPETITIVE LANDSCAPE ........................... 81
10.1 OVERVIEW ............................................................................. 81
10.2 MARKET SHARE ANAYISIS ..................................................... 82
10.3 COMPETITIVE BENCHMARKING ............................................. 83
10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL ISCHEMIC STROKE SURGERY MARKET ............................................ 84
10.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ISCHEMIC STROKE SURGERY
MARKET .............. 84
10.6 KEY DEVELOPMENT ANALYSIS .............................................. 85
10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES ....................... 85
10.7.1 MERGER & ACQUISITIONS .................................................. 86
10.7.2 AGREEMENT/MARKETING STRATEGIES.............................. 86
10.8 FINANCIAL MATRIX ............................................................... 87
10.8.1 SALES (USD MILLION), 2021 .............................................. 87
10.8.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021 ................................................................... 87
11 COMPANY PROFILES ..................................... 88
11.1 MEDTRONIC PLC ................................................................... 88
11.1.1 COMPANY OVERVIEW ........................................................ 88
11.1.2 FINANCIAL OVERVIEW ....................................................... 89
11.1.3 PRODUCTS/SERVICES OFFERED ......................................... 89
11.1.4 KEY DEVELOPMENTS ......................................................... 90
11.1.5 SWOT ANALYSIS ............................................................... 90
11.1.6 KEY STRATEGIES ............................................................... 90
11.2 ABBOTT LABORATORIES ........................................................ 91
11.2.1 COMPANY OVERVIEW ........................................................ 91
11.2.2 FINANCIAL OVERVIEW ....................................................... 92
11.2.3 PRODUCTS/SERVICES OFFERED ......................................... 92
11.2.4 KEY DEVELOPMENTS ......................................................... 93
11.2.5 KEY STRATEGIES ............................................................... 93
11.3 BOSTON SCIENTIFIC CORPORATION ...................................... 94
11.3.1 COMPANY OVERVIEW ........................................................ 94
11.3.2 FINANCIAL OVERVIEW ....................................................... 94
11.3.3 PRODUCTS/SERVICES OFFERED ......................................... 95
11.3.4 KEY DEVELOPMENTS ......................................................... 95
11.3.5 KEY STRATEGIES ............................................................... 95
11.4 CORDIS CORPORATION .......................................................... 96
11.4.1 COMPANY OVERVIEW ........................................................ 96
11.4.2 FINANCIAL OVERVIEW ....................................................... 96
11.4.3 PRODUCTS/SERVICES OFFERED ......................................... 96
11.4.4 KEY DEVELOPMENTS ......................................................... 96
11.4.5 KEY STRATEGIES ............................................................... 96
11.5 KONINKLIJKE PHILIPS N.V ..................................................... 97
11.5.1 COMPANY OVERVIEW ........................................................ 97
11.5.2 FINANCIAL OVERVIEW ....................................................... 98
11.5.3 PRODUCTS/SERVICES OFFERED ......................................... 98
11.5.4 KEY DEVELOPMENTS ......................................................... 99
11.5.5 SWOT ANALYSIS ............................................................... 99
11.5.6 KEY STRATEGIES ............................................................... 99
11.6 STRYKER ............................................................................... 100
11.6.1 COMPANY OVERVIEW ........................................................ 100
11.6.2 FINANCIAL OVERVIEW ....................................................... 101
11.6.3 PRODUCTS OFFERED ......................................................... 102
11.6.4 KEY DEVELOPMENTS ......................................................... 102
11.6.5 SWOT ANALYSIS ............................................................... 103
1 1.6.6 KEY STRATEGIES ............................................................... 103
11.7 IMPERATIVE CARE ................................................................. 104
11.7.1 COMPANY OVERVIEW ........................................................ 104
11.7.2 FINANCIAL OVERVIEW ....................................................... 104
11.7.3 PRODUCTS OFFERED ......................................................... 104
11.7.4 KEY DEVELOPMENTS ......................................................... 104
11.7.5 KEY STRATEGIES ............................................................... 105
11.8 JOHNSON & JOHNSON SERVICES, INC. .................................. 106
11.8.1 COMPANY OVERVIEWS ...................................................... 106
11.8.2 FINANCIAL OVERVIEW ....................................................... 106
11.8.3 PRODUCTS OFFERED ......................................................... 107
11.8.4 KEY DEVELOPMENTS ......................................................... 107
11.8.5 SWOT ANALYSIS ............................................................... 108
11.8.6 KEY STRATEGIES ............................................................... 108
11.9 PENUMBRA, INC. ................................................................... 109
11.9.1 COMPANY OVERVIEW ........................................................ 109
11.9.2 FINANCIAL OVERVIEW ....................................................... 109
11.9.3 PRODUCTS OFFERED ......................................................... 110
11.9.4 KEY DEVELOPMENTS ......................................................... 110
11.9.5 SWOT ANALYSIS ............................................................... 111
11.9.6 KEY STRATEGIES ............................................................... 111
11.10 PHENOXYHENOX GMBH ........................................................ 112
11.10.1 COMPANY OVERVIEW ........................................................ 112
11.10.2 FINANCIAL OVERVIEW ....................................................... 112
11.10.3 PRODUCTS OFFERED ......................................................... 112
11.10.4 KEY DEVELOPMENTS ......................................................... 112
11.10.5 KEY STRATEGIES ............................................................... 112
12 APPENDIX........................................................ 113
12.1 REFERENCES ......................................................................... 113
12.2 RELATED REPORTS ................................................................ 114